Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7470085 | 0.88 | SLC10A2 (0.33) | MAPK1TDP1CHRM1MAPK10 | |
| SCHEMBL7472192 | 0.88 | SLC10A2 (0.33) | MAPK1TDP1CHRM1MAPK10 | |
| SCHEMBL2589896 | 0.87 | MAPK1 (0.35) | MAPK1TDP1CHRM1 | |
| SCHEMBL2590605 | 0.84 | FGFR1 (0.34) | MAPK1TDP1MAPT | |
| SCHEMBL2589232 | 0.82 | SLC10A2 (0.33) | MAPT | |
| SCHEMBL2589094 | 0.82 | MAOA (0.37) | — | |
| SCHEMBL19170232 | 0.82 | CDK4 (0.32) | MAPK10 | |
| SCHEMBL7469254 | 0.79 | EGFR (0.40) | CHRM1MAPTPTPN1 | |
| SCHEMBL7463854 | 0.79 | EGFR (0.40) | CHRM1MAPTPTPN1 | |
| SCHEMBL17506155 | 0.79 | DRD2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029938-A1 | Chemical Compounds | CYP11B1, GOT2, CYP11B2 | MAPK1 1737/4885TDP1 3688/4885CHRM1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.